euro adhoc: Marseille-Kliniken AG / Dividend Announcements/Distribution / - Dividend increased thanks to positive earnings advance to EUR 0.45 - Majority shareholder family waives disbursement of its

--------------------------------------------------------------------------------
Disclosure announcement transmitted by euro adhoc. The issuer is responsible
for the content of this announcement.
--------------------------------------------------------------------------------

27.10.2006

Berlin, 27. October 2006. Marseille-Kliniken AG, (Prime Standard,
ISIN DE 0007783003, MKA) will continue its shareholder-friendly
dividend distribution policy this year thanks to the positive
development of the Group’s annual profits rise from EUR 6.3 last year
to EUR 9.7 million in fiscal year 2005/2006. Management and
supervisory board will propose the resolution of a dividend
distribution of EUR 0.45 per share at the shareholder meeting slated
to be held on December 6, 2006.

The dividend of EUR 0.45 per dividend-eligible share includes a
special dividend of EUR 0.20 to be paid in connection with the sale
and leaseback transactions contracted in FY 2005/2006.

The Marseille family, who holds a stake of approximately 60% in the
company will waive its dividend disbursement this year. As a result,
the total amount of dividends to be distributed is reduced by EUR 3.3
million to EUR 2.2 million. The Marseille is foregoing its share in
the dividend to commit additional resources to the further
acceleration of the company’s expansion and to consequently increase
its goodwill.

End of the Ad hoc release

FY 2005/2006: The Marseille-Kliniken AG, (Prime Standard, ISIN DE
0007783003, MKA) is continuing to grow and is recording above-average
results. In the financial year of 2005/06 the company’s turnover
increased to 210.4 million Euros (previous year: 201.5 million
Euros). The EBIT result according to IFRS improved from 23.1 million
Euros in the previous year to 25.8 million Euros in the year under
review. The company’s annual surplus improved from 6.3 million Euros
to 9.7 million Euros. The DVFA/SG (IFRS) adjusted result was 9.3
million Euro in the financial year compared to 8.9 million Euros the
previous year. Per share this is equal to a result increase of 0.03
Euro to 0.76 Euro (previous year: 0.73 Euro). The equity capital
recorded on the balance sheet is 66.8 million Euros as against 62.6
million Euros in the previous year, which equates to a capital ratio
of 20.7% (previous year 15.5%).

end of announcement euro adhoc 27.10.2006 06:58:38
--------------------------------------------------------------------------------

ots Originaltext: Marseille-Kliniken AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:
Marseille-Kliniken AG Hillermann Consulting
Axel Hölzer Christian Hillermann
CEO Investor Relations
Alte Jakobstraße 79/80 Eppendorfer Baum 5
10709 Berlin, Germany 20249 Hamburg, Germany
Tel.: 49-(0)30 / 246 32-400 Tel.: 49-(0)40 / 414 069-13
Fax: 49-(0)30 / 246 32-401 Fax: 49-(0)40 / 414 069-14

Branche: Pharmaceuticals
ISIN: DE0007783003
WKN: 778300
Index: CDAX, Classic All Share, Prime All Share
Börsen: Frankfurter Wertpapierbörse / official dealing/prime standard
Börse Berlin-Bremen / free trade
Baden-Württembergische Wertpapierbörse / free trade
Börse Düsseldorf / free trade
Hamburger Wertpapierbörse / official dealing